Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
The Institute of Cancer Research
Headquarters: London, United Kingdom
Website: http://www.icr.ac.uk
Year Founded: 1909
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Aug 2, 2024
Distillery Therapeutics
Inhibiting NBS1 lactylation for chemotherapy resistance
BioCentury | Oct 20, 2023
Discovery & Translation
Targeted protein degrader design insights; plus Long COVID, obesity and more
BioCentury’s roundup of translational innovations
BioCentury | May 27, 2020
Emerging Company Profile
Versant’s Monte Rosa debuts with $32.5M, library of molecular glues for protein degradation
Versant-built start-up finds targets, compounds for protein degradation via structural biology and proteomics
BioCentury | Feb 29, 2020
Translation in Brief
Genentech finds non-exhausted antitumor T cell source in blood, plus updates on Penn and Chordoma Foundation-Mark Foundation
BioCentury’s roundup of preclinical news
BioCentury | Oct 16, 2019
Company News
AI play Healx raises $56M to repurpose drugs for rare disease
How Healx is tackling rare diseases using AI and input from patient groups
BioCentury | Oct 11, 2019
Preclinical News
Oct. 10 Preclinical Quick Takes: Merck-Prokaryotics Inc.-Princeton ID new antibiotic class; plus NIH, Owkin, Genentech and ICR
BioCentury | Jun 3, 2019
Clinical News
June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more
BioCentury | May 31, 2019
Targets & Mechanisms
Targeting cancer evolution offers a way to foil drug resistance
Solutions to cancer drug resistance could come from new understanding about tumor evolution and advances in liquid biopsies.
Items per page:
1 - 10 of 130